首页> 美国卫生研究院文献>JCI Insight >MicroRNA-125a and -b inhibit A20 and MAVS to promote inflammation and impair antiviral response in COPD
【2h】

MicroRNA-125a and -b inhibit A20 and MAVS to promote inflammation and impair antiviral response in COPD

机译:MicroRNA-125a和-b抑制A20和MAVS促进炎症并削弱COPD中的抗病毒反应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Influenza A virus (IAV) infections lead to severe inflammation in the airways. Patients with chronic obstructive pulmonary disease (COPD) characteristically have exaggerated airway inflammation and are more susceptible to infections with severe symptoms and increased mortality. The mechanisms that control inflammation during IAV infection and the mechanisms of immune dysregulation in COPD are unclear. We found that IAV infections lead to increased inflammatory and antiviral responses in primary bronchial epithelial cells (pBECs) from healthy nonsmoking and smoking subjects. In pBECs from COPD patients, infections resulted in exaggerated inflammatory but deficient antiviral responses. A20 is an important negative regulator of NF-κB–mediated inflammatory but not antiviral responses, and A20 expression was reduced in COPD. IAV infection increased the expression of miR-125a or -b, which directly reduced the expression of A20 and mitochondrial antiviral signaling (MAVS), and caused exaggerated inflammation and impaired antiviral responses. These events were replicated in vivo in a mouse model of experimental COPD. Thus, miR-125a or -b and A20 may be targeted therapeutically to inhibit excessive inflammatory responses and enhance antiviral immunity in IAV infections and in COPD.
机译:甲型流感病毒(IAV)感染导致呼吸道严重炎症。患有慢性阻塞性肺疾病(COPD)的患者通常具有夸大的气道炎症,并且更容易感染具有严重症状和死亡率的疾病。目前尚不清楚在IAV感染期间控制炎症的机制以及COPD中免疫失调的机制。我们发现,IAV感染导致健康非吸烟者和吸烟者的原发性支气管上皮细胞(pBECs)中的炎症和抗病毒反应增加。在COPD患者的pBEC中,感染导致炎症反应过度但抗病毒反应不足。 A20是NF-κB介导的炎症反应而非抗病毒反应的重要负调节剂,COPD中A20表达降低。 IAV感染会增加miR-125a或-b的表达,从而直接降低A20和线粒体抗病毒信号(MAVS)的表达,并导致炎症反应加剧和抗病毒反应减弱。这些事件在实验性COPD的小鼠模型中体内复制。因此,miR-125a或-b和A20可在治疗上靶向抑制IAV感染和COPD中过度的炎症反应并增强抗病毒免疫力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号